✦ LIBER ✦

A pilot phase IV open label study investigating the safety and tolerability of switching from the Exelon patch 9.5mg daily to Aricept 23mg daily in patients with moderate to severe AD

✍ Scribed by Sabbagh, Marwan; Syal, Atul; Obradov, Zoran; Kahlon, Maninder; Jacobson, Sandra; Shah, Jatin; Liebsack, Carolyn; Belden, Christine; Shutts, Tammy; Malek-Ahmadi, Michael; Kratz, Kris; Klinck, Brian

Book ID: 122491101
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 51 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.09.131

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 24-week, open-label extension to the A

A 24-week, open-label extension to the ACTivities of daily living and cognitION (ACTION) study: Long-term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease

✍ Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Moniq 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB